The New Carl Icahn’s Icahn Carl C Holding in Enzon Pharmaceuticals, Inc
Icahn Carl C filed with the SEC SC 13D/A form for Enzon Pharmaceuticals, Inc. The form can be accessed here: 000092846416000246. As reported in Carl Icahn’s Icahn Carl C’s form, the filler as of late owns 14.92% or 6,598,886 shares of the Health Care–company.
Enzon Pharmaceuticals, Inc stake is a new one for the for the hedge fund and it was filed because of activity on November 28, 2016. We feel this shows Carl Icahn’s Icahn Carl C’s positive view for the stock.
The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Carl Icahn’s Icahn Carl C’s US equities portfolio is in this sector.
Enzon Pharmaceuticals, Inc Institutional Sentiment
Latest Security and Exchange filings show 49 investors own Enzon Pharmaceuticals, Inc. The institutional ownership in Q3 2015 is low, at 51.79% of the outstanding shares. This is increased by 4016213 the total institutional shares. 22720533 were the shares owned by these institutional investors. In total 7 funds opened new Enzon Pharmaceuticals, Inc stakes, 14 increased stakes. There were 11 that closed positions and 13 reduced them.
Globeflex Capital L P is an institutional investor bullish on Enzon Pharmaceuticals, Inc, owning 250761 shares as of Q3 2015 for 0.05% of its portfolio. Bogle Investment Management Lp owns 110202 shares or 0.01% of its portfolio. IN Monarch Capital Management Inc have less than 0.01% of their stock portfolio for 10000 shares. Further, James Investment Research Inc reported stake worth less than 0.01% of its US stock portfolio. The NY Icahn Carl C owns 5904863 shares. Enzon Pharmaceuticals, Inc is 0.02% of the manager’s US portfolio.
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn’s disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Insitutional Activity: The institutional sentiment increased to 0.17 in Q2 2016. Its up 0.07, from 0.1 in 2016Q1. The ratio improved, as 28 funds sold all Enzon Pharmaceuticals Inc shares owned while 1 reduced positions. 2 funds bought stakes while 1 increased positions. They now own 496,751 shares or 97.00% less from 16.53 million shares in 2016Q1.
Moreover, Monarch Management Inc has 0% invested in Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) for 10,000 shares. Ancora Advsrs Ltd Llc owns 50,000 shares or 0% of their US portfolio. Next Group owns 60 shares or 0% of their US portfolio. Tradewinds Cap Management Limited Co holds 0% of its portfolio in Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) for 200 shares. Kistler owns 825 shares or 0% of their US portfolio. Acadian Asset Management Limited Com holds 122,287 shares or 0% of its portfolio. Tudor Investment Et Al accumulated 47,998 shares or 0% of the stock. California Pub Employees Retirement System accumulated 254,200 shares or 0% of the stock.
The stock decreased 4.71% or $0.02 during the last trading session, hitting $0.405. Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) has declined 18.00% since April 26, 2016 and is downtrending. It has underperformed by 23.26% the S&P500.
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The company has a market cap of $17.91 million. The Firm has no clinical activities and limited corporate operations. It has a 0.62 P/E ratio. PegIntron is used both as a monotherapy and in combination with REBETOL capsules for the treatment of chronic hepatitis C.
More important recent Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on November 09, 2009, also Thestreet.com published article titled: “Enzon Pharmaceuticals Inc Stock Upgraded (ENZN)”, Seekingalpha.com published: “Enzon Pharmaceuticals Selling Well Below Likely Future Distributions” on May 25, 2016. More interesting news about Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) was released by: Seekingalpha.com and their article: “Warning! Enzon Pharmaceuticals Is Definitely Going To $0” with publication date: January 14, 2014.
According to Zacks Investment Research, “Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company’s marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn’s disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.”
ENZN Company Profile
Enzon Pharmaceuticals, Inc., incorporated on May 11, 1983, receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Firm has no clinical activities and limited corporate operations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.